Analyze Diet
Current microbiology2013; 68(3); 352-357; doi: 10.1007/s00284-013-0483-6

Study of lysozyme resistance in Rhodococcus equi.

Abstract: Lysozyme is an important and widespread component of the innate immune response that constitutes the first line of defense against bacterial pathogens. The bactericidal effect of this enzyme relies on its capacity to hydrolyze the bacterial cell wall and also on a nonenzymatic mechanism involving its cationic antimicrobial peptide (CAMP) properties, which leads to membrane permeabilization. In this paper, we report our findings on the lysozyme resistance ability of Rhodococcus equi, a pulmonary pathogen of young foals and, more recently, of immunocompromised patients, whose pathogenic capacity is conferred by a large virulence plasmid. Our results show that (i) R. equi can be considered to be moderately resistant to lysozyme, (ii) the activity of lysozyme largely depends on its muramidase action rather than on its CAMP activity, and (iii) the virulence plasmid confers part of its lysozyme resistance capacity to R. equi. This study is the first one to demonstrate the influence of the virulence plasmid on the stress resistance capacity of R. equi and improves our understanding of the mechanisms enabling R. equi to resist the host defenses.
Publication Date: 2013-10-30 PubMed ID: 24170270DOI: 10.1007/s00284-013-0483-6Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article investigates the resistance of Rhodococcus equi, a bacterium that causes illness in foals and immunocompromised humans, to attack by the lysozyme enzyme, a key part of the body’s initial immune response. The finding is that R. equi is moderately resistant to lysozyme, mostly due to a large virulence plasmid, and that the enzyme’s action is mainly due to its ability to break down the bacterial cell wall, not its antimicrobial properties.

Introduction

  • The focus of this research is on the bacterial pathogen Rhodococcus equi. This bacterium is known to cause pulmonary diseases in young foals and also affects immunocompromised patients.
  • The researchers are interested in studying the organism’s resistance to the antimicrobial enzyme lysozyme, which functions as part of the innate immune response.

Lysozyme Resistance in R. equi

  • In their experiments, the researchers found that R. equi can be categorized as moderately resistant to lysozyme.
  • The activity of lysozyme against this bacterium primarily utilises its muramidase action to hydrolyze the bacterial cell wall, as opposed to its cationic antimicrobial peptide (CAMP) properties.

Significance of the Virulence Plasmid on Stress Resistance

  • The researchers have found that the virulence plasmid of R. equi confers additional resistance capability against lysozyme to the bacterium.
  • This study is the first of its kind to highlight the critical role of the virulence plasmid of R. equi in contributing to its stress resistance capacity.
  • The findings add to our understanding of how R. equi can resist host defenses, which could potentially guide new treatment strategies against infections caused by this bacterium.

Cite This Article

APA
Hébert L, Bidaud P, Goux D, Benachour A, Laugier C, Petry S. (2013). Study of lysozyme resistance in Rhodococcus equi. Curr Microbiol, 68(3), 352-357. https://doi.org/10.1007/s00284-013-0483-6

Publication

ISSN: 1432-0991
NlmUniqueID: 7808448
Country: United States
Language: English
Volume: 68
Issue: 3
Pages: 352-357

Researcher Affiliations

Hébert, Laurent
  • Dozulé Laboratory for Equine Diseases, Bacteriology and Parasitology Unit, ANSES, 14430, Goustranville, France, laurent.hebert@anses.fr.
Bidaud, Pauline
    Goux, Didier
      Benachour, Abdellah
        Laugier, Claire
          Petry, Sandrine

            MeSH Terms

            • Antimicrobial Cationic Peptides / metabolism
            • Drug Resistance, Bacterial
            • Genes, Bacterial
            • Muramidase / metabolism
            • Plasmids
            • Rhodococcus equi / drug effects
            • Rhodococcus equi / genetics

            References

            This article includes 25 references
            1. Giguère S, Cohen ND, Chaffin MK, Hines SA, Hondalus MK, Prescott JF, Slovis NM. Rhodococcus equi: clinical manifestations, virulence, and immunity.. J Vet Intern Med 2011 Nov-Dec;25(6):1221-30.
            2. Hondalus MK, Mosser DM. Survival and replication of Rhodococcus equi in macrophages.. Infect Immun 1994 Oct;62(10):4167-75.
            3. Vandal OH, Roberts JA, Odaira T, Schnappinger D, Nathan CF, Ehrt S. Acid-susceptible mutants of Mycobacterium tuberculosis share hypersusceptibility to cell wall and oxidative stress and to the host environment.. J Bacteriol 2009 Jan;191(2):625-31.
              pubmed: 19011036doi: 10.1128/JB.00932-08google scholar: lookup
            4. Takai S, Hines SA, Sekizaki T, Nicholson VM, Alperin DA, Osaki M, Takamatsu D, Nakamura M, Suzuki K, Ogino N, Kakuda T, Dan H, Prescott JF. DNA sequence and comparison of virulence plasmids from Rhodococcus equi ATCC 33701 and 103.. Infect Immun 2000 Dec;68(12):6840-7.
            5. Perez MG, Vassilev T, Kemmerly SA. Rhodococcus equi infection in transplant recipients: a case of mistaken identity and review of the literature.. Transpl Infect Dis 2002 Mar;4(1):52-6.
            6. Bidaud P, Hébert L, Barbey C, Appourchaux AC, Torelli R, Sanguinetti M, Laugier C, Petry S. Rhodococcus equi's extreme resistance to hydrogen peroxide is mainly conferred by one of its four catalase genes.. PLoS One 2012;7(8):e42396.
              pubmed: 22879963doi: 10.1371/journal.pone.0042396google scholar: lookup
            7. von Bargen K, Haas A. Molecular and infection biology of the horse pathogen Rhodococcus equi.. FEMS Microbiol Rev 2009 Sep;33(5):870-91.
            8. Kedlaya I, Ing MB, Wong SS. Rhodococcus equi infections in immunocompetent hosts: case report and review.. Clin Infect Dis 2001 Feb 1;32(3):E39-46.
              pubmed: 11170969doi: 10.1086/318520google scholar: lookup
            9. Benoit S, Taouji S, Benachour A, Hartke A. Resistance of Rhodococcus equi to acid pH.. Int J Food Microbiol 2000 Apr 10;55(1-3):295-8.
              pubmed: 10791761doi: 10.1016/s0168-1605(00)00172-0google scholar: lookup
            10. Scheurwater E, Reid CW, Clarke AJ. Lytic transglycosylases: bacterial space-making autolysins.. Int J Biochem Cell Biol 2008;40(4):586-91.
              pubmed: 17468031doi: 10.1016/j.biocel.2007.03.018google scholar: lookup
            11. Takai S, Sekizaki T, Ozawa T, Sugawara T, Watanabe Y, Tsubaki S. Association between a large plasmid and 15- to 17-kilodalton antigens in virulent Rhodococcus equi.. Infect Immun 1991 Nov;59(11):4056-60.
            12. Letek M, González P, Macarthur I, Rodríguez H, Freeman TC, Valero-Rello A, Blanco M, Buckley T, Cherevach I, Fahey R, Hapeshi A, Holdstock J, Leadon D, Navas J, Ocampo A, Quail MA, Sanders M, Scortti MM, Prescott JF, Fogarty U, Meijer WG, Parkhill J, Bentley SD, Vázquez-Boland JA. The genome of a pathogenic rhodococcus: cooptive virulence underpinned by key gene acquisitions.. PLoS Genet 2010 Sep 30;6(9):e1001145.
              pubmed: 20941392doi: 10.1371/journal.pgen.1001145google scholar: lookup
            13. Fahlgren A, Hammarström S, Danielsson A, Hammarström ML. Increased expression of antimicrobial peptides and lysozyme in colonic epithelial cells of patients with ulcerative colitis.. Clin Exp Immunol 2003 Jan;131(1):90-101.
            14. Flores AR, Parsons LM, Pavelka MS Jr. Characterization of novel Mycobacterium tuberculosis and Mycobacterium smegmatis mutants hypersusceptible to beta-lactam antibiotics.. J Bacteriol 2005 Mar;187(6):1892-900.
            15. Makrai L, Takayama S, Dénes B, Hajtós I, Sasaki Y, Kakuda T, Tsubaki S, Major A, Fodor L, Varga J, Takai S. Characterization of virulence plasmids and serotyping of rhodococcus equi isolates from submaxillary lymph nodes of pigs in Hungary.. J Clin Microbiol 2005 Mar;43(3):1246-50.
            16. Hébert L, Courtin P, Torelli R, Sanguinetti M, Chapot-Chartier MP, Auffray Y, Benachour A. Enterococcus faecalis constitutes an unusual bacterial model in lysozyme resistance.. Infect Immun 2007 Nov;75(11):5390-8.
              pubmed: 17785473doi: 10.1128/IAI.00571-07google scholar: lookup
            17. Le Jeune A, Torelli R, Sanguinetti M, Giard JC, Hartke A, Auffray Y, Benachour A. The extracytoplasmic function sigma factor SigV plays a key role in the original model of lysozyme resistance and virulence of Enterococcus faecalis.. PLoS One 2010 Mar 11;5(3):e9658.
              pubmed: 20300180doi: 10.1371/journal.pone.0009658google scholar: lookup
            18. Bruhn O, Grötzinger J, Cascorbi I, Jung S. Antimicrobial peptides and proteins of the horse--insights into a well-armed organism.. Vet Res 2011 Sep 2;42(1):98.
              pubmed: 21888650doi: 10.1186/1297-9716-42-98google scholar: lookup
            19. Herbert S, Bera A, Nerz C, Kraus D, Peschel A, Goerke C, Meehl M, Cheung A, Götz F. Molecular basis of resistance to muramidase and cationic antimicrobial peptide activity of lysozyme in staphylococci.. PLoS Pathog 2007 Jul 27;3(7):e102.
              pubmed: 17676995doi: 10.1371/journal.ppat.0030102google scholar: lookup
            20. von Bargen K, Polidori M, Becken U, Huth G, Prescott JF, Haas A. Rhodococcus equi virulence-associated protein A is required for diversion of phagosome biogenesis but not for cytotoxicity.. Infect Immun 2009 Dec;77(12):5676-81.
              pubmed: 19797071doi: 10.1128/IAI.00856-09google scholar: lookup
            21. Veiga P, Bulbarela-Sampieri C, Furlan S, Maisons A, Chapot-Chartier MP, Erkelenz M, Mervelet P, Noirot P, Frees D, Kuipers OP, Kok J, Gruss A, Buist G, Kulakauskas S. SpxB regulates O-acetylation-dependent resistance of Lactococcus lactis peptidoglycan to hydrolysis.. J Biol Chem 2007 Jul 6;282(27):19342-54.
              pubmed: 17485463doi: 10.1074/jbc.M611308200google scholar: lookup
            22. Topino S, Galati V, Grilli E, Petrosillo N. Rhodococcus equi infection in HIV-infected individuals: case reports and review of the literature.. AIDS Patient Care STDS 2010 Apr;24(4):211-22.
              pubmed: 20377432doi: 10.1089/apc.2009.0248google scholar: lookup
            23. Vollmer W, Tomasz A. Peptidoglycan N-acetylglucosamine deacetylase, a putative virulence factor in Streptococcus pneumoniae.. Infect Immun 2002 Dec;70(12):7176-8.
            24. Benachour A, Ladjouzi R, Le Jeune A, Hébert L, Thorpe S, Courtin P, Chapot-Chartier MP, Prajsnar TK, Foster SJ, Mesnage S. The lysozyme-induced peptidoglycan N-acetylglucosamine deacetylase PgdA (EF1843) is required for Enterococcus faecalis virulence.. J Bacteriol 2012 Nov;194(22):6066-73.
              pubmed: 22961856doi: 10.1128/JB.00981-12google scholar: lookup
            25. Zhang X, Paganelli FL, Bierschenk D, Kuipers A, Bonten MJ, Willems RJ, van Schaik W. Genome-wide identification of ampicillin resistance determinants in Enterococcus faecium.. PLoS Genet 2012 Jun;8(6):e1002804.
              pubmed: 22761597doi: 10.1371/journal.pgen.1002804google scholar: lookup

            Citations

            This article has been cited 1 times.
            1. Nahar A, Baker AL, Nichols DS, Bowman JP, Britz ML. Benchmarking DNA Extraction Methods for Phylogenomic Analysis of Sub-Antarctic Rhodococcus and Williamsia Species.. Microorganisms 2021 Jun 9;9(6).
              doi: 10.3390/microorganisms9061253pubmed: 34207615google scholar: lookup